Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenyi capsule
- Development stage
- Unknown
- Lead developer
- Dalian Yalifeng Biopharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Shenyi capsule is an oral anticancer pharmaceutical containing ginsenoside Rg3, a tetracyclic triterpenoid saponin extracted from the root of *Panax ginseng*. Developed by Dalian ShenFeng Pharmaceutical, it was the first Class I innovative traditional Chinese medicine approved by the China National Medical Products Administration (NMPA). The drug is primarily utilized as an adjuvant therapy in oncology, particularly for non-small cell lung cancer (NSCLC) and gastric cancer, where it is used in combination with chemotherapy to enhance therapeutic efficacy and mitigate side effects. In the context of hepatocellular carcinoma (HCC), Shenyi capsule is being investigated for its potential to prevent postoperative recurrence following radical resection. Its mechanism of action is multi-faceted, involving the inhibition of tumor angiogenesis by downregulating vascular endothelial growth factor (VEGF), the induction of apoptosis in cancer cells through the regulation of Bcl-2 and Caspase-3, and the modulation of the host immune system by enhancing the activity of T-lymphocytes and natural killer cells.
- Brand names
- ShenyiShen Yi
- Other names
- ginsenoside Rg3Ginsenoside Rg3 capsuleShenyi capsule
02
Targets
BCL-2 (BCL-2 family)CASP3 (Caspase-3)CASP8 (Caspase-8)CASP9 (Caspase-9)MMP9 (Matrix metalloproteinase-9)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on Shenyi capsule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenyi capsule.